NEW YORK (GenomeWeb News) – DV Biologics and System Biosciences this week announced a partnership to develop human-derived, disease-specific induced pluripotent stem cell lines.
Under the terms of the deal, System Biosciences will convert many of DV Biologics' disease-specific cell types into iPSCs, using its proprietary products for reprogramming and iPSC generation, the two firms said in a statement.
System Biosciences will exclusively market several iPSCs developed under the agreement. No financial terms of the deal were disclosed.
DV Biologics is headquartered in Costa Mesa, Calif., and is a supplier of human primary cells and cell-derived products. System Biosciences is based in Mountain View, Calif., and develops and commercializes technologies for genomic- and proteomic-based investigations.